Application of VCAM1-CD49d signaling pathway inhibitors in the preparation of drugs for treating tumors

By combining an inhibitor targeting the VCAM1-CD49d signaling pathway with lymphocyte immunotherapy, the problem of abnormal iNKT cell function in the tumor microenvironment was addressed, enhancing the infiltration and anti-tumor function of lymphocytes in tumor tissue and significantly inhibiting tumor growth.

CN117159714BActive Publication Date: 2026-11-17UNIV OF SCI & TECH OF CHINA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310986666.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-07
Publication Date
2026-11-17
Estimated Expiration
2043-08-07

AI Technical Summary

Technical Problem

The abnormal function of iNKT cells in the existing tumor microenvironment affects their anti-tumor effects, and new regulatory mechanisms are needed to enhance the infiltration and immune response of iNKT cells.

Method used

Inhibitors targeting the VCAM1-CD49d signaling pathway, when combined with lymphocyte immunotherapy, including iNKT cells, CD8 T cells, NK cells, and MAIT cells, can enhance lymphocyte infiltration and anti-tumor function in tumor tissues by inhibiting or knocking out proteins or genes related to the VCAM1-CD49d signaling pathway.

Benefits of technology

It significantly enhanced the infiltration and anti-tumor function of iNKT cells, CD8 T cells and NK cells, synergistically inhibited tumor growth, and improved the efficacy of tumor treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004383570500000011
    Figure HDA0004383570500000011
  • Figure HDA0004383570500000012
    Figure HDA0004383570500000012
  • Figure HDA0004383570500000021
    Figure HDA0004383570500000021
Patent Text Reader

Abstract

This invention relates to the field of biomedical technology, and more particularly to the application of VCAM1-CD49d signaling pathway inhibitors in the preparation of drugs for treating tumors. The invention has found that knocking down the tumor Vcam1 gene can enhance iNKT cell infiltration and immune response, thereby strengthening iNKT cell-mediated anti-tumor effects; and that combining VCAM1 antibody blockade therapy or CD49d antibody blockade therapy with iNKT cell therapy synergistically inhibits tumor growth. These results confirm that the VCAM1-CD49d signaling pathway is a novel target for regulating iNKT cell infiltration and anti-tumor function, providing important evidence for new strategies to improve the efficacy of iNKT cell-related therapies, and possessing significant clinical application prospects and value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to the application of VCAM1-CD49d signaling pathway inhibitors in the preparation of drugs for treating tumors. Background Technology

[0002] Cancer is one of the leading causes of death worldwide. Current treatments primarily include chemotherapy and radiotherapy, but these methods have limited effectiveness and serious side effects. Therefore, more effective and safer new approaches are needed to treat cancer. Immunotherapy works by reversing the immunosuppressive state of the tumor microenvironment, thereby enabling the tumor immune system to exert anti-tumor effects and inhibiting tumor growth and metastasis. Thus, immunotherapy has become one of the most promising cancer treatment strategies. Current research on immunotherapy mainly focuses on three directions: inhibiting immune checkpoints, adoptive transfer of immune cells, and chimeric antigen receptor (CAR) cell therapy (Nelson, Lukacs et al. 2021).

[0003] iNKT cells are a type of intrinsic T lymphocyte. iNKT cells interact with various immune cells, regulating homeostasis and balance in the body (Brennan, Brigli et al. 2013). Further research has revealed that iNKT cells participate in the regulation of various diseases, including viral infections, inflammation, and tumors. Based on the immune surveillance function of iNKT cells and their direct or indirect anti-tumor functions, iNKT cell immunotherapy shows promising application prospects (Fujii and Shimizu 2019). However, existing studies have demonstrated that lactate accumulation, impaired lipid synthesis, and abnormal glycolysis in the tumor microenvironment lead to abnormal iNKT cell function within the tumor, thus hindering the anti-tumor function of iNKT cells (Xie, Zhu et al. 2016, Fu, Zhu et al. 2019, Fu, He et al. 2020). Moreover, the number of iNKT cells in tumor tissue is positively correlated with the prognosis of cancer patients, indicating that iNKT cell infiltration is one of the factors affecting the efficacy of iNKT cell therapy (Tang, Liu et al. 2021). Therefore, exploring the dynamic regulatory mechanisms affecting iNKT cell infiltration and activation, and discovering key regulatory molecules, will help provide new treatment options for improving the efficacy of iNKT cell immunotherapy. Summary of the Invention

[0004] In view of this, the present invention provides the application of VCAM1-CD49d signaling pathway inhibitors in the preparation of drugs for treating tumors.

[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0006] The application of the VCAM1-CD49d signaling pathway as a target for tumor treatment, or the VCAM1-CD49d signaling pathway combined with lymphocyte immunotherapy as a target for tumor treatment in drug preparation;

[0007] The lymphocytes include at least one of iNKT cells, CD8 T cells, NK cells, and MAIT cells.

[0008] Application of inhibitors targeting the VCAM1-CD49d signaling pathway, either alone or in combination with lymphocyte immunotherapy agents, in the preparation of drugs for the prevention and / or treatment of tumors;

[0009] The lymphocyte immunomodulators include lymphocytes and / or lymphocyte agonists;

[0010] The lymphocytes include at least one of iNKT cells, CD8 T cells, NK cells, and MAIT cells;

[0011] The lymphocyte agonists include αGalCer, PBS57, αGC acC8, αGC acC20:2, and OCH.

[0012] In this invention, the inhibitor is at least one of 1) to 3):

[0013] 1) Substances that inhibit the protein activity of proteins related to the VCAM1-CD49d signaling pathway;

[0014] 2) Substances that degrade proteins related to the VCAM1-CD49d signaling pathway;

[0015] 3) Substances that inhibit the synthesis of proteins related to the VCAM1-CD49d signaling pathway;

[0016] 4) Preparations that knock out or knock down genes related to the VCAM1-CD49d signaling pathway.

[0017] Any form of inhibition, silencing, knockout, or reduction of expression of proteins or genes related to the VCAM1-CD49d signaling pathway (such as VCAM1 and CD49d) can enhance the tumor-suppressing effect of iNKT cells. Combining these with iNKT cell therapy can synergistically inhibit the tumor growth process, resulting in a more significant anti-tumor effect.

[0018] In some implementations, the VCAM1-CD49d signaling pathway-related proteins are VCAM1 and / or CD49d;

[0019] The genes associated with the VCAM1-CD49d signaling pathway are VCAM1 and / or ITGA4.

[0020] In some embodiments, the substances described in 1) to 3) are antibodies or small molecule drugs targeting the VCAM1-CD49d signaling pathway. In some specific embodiments, the inhibitors targeting the VCAM1-CD49d signaling pathway are anti-VCAM1 antibodies and / or anti-CD49d antibodies; the small molecule drugs are Firategrast, ATL 1102, TCS 2314, Surfactin C1, or CAM741. Firategrast, ATL 1102, and TCS 2314 are CD49d antagonist drugs; Surfactin C1 and CAM741 are VCAM1 antagonist drugs.

[0021] In some embodiments, in the formulations for knocking out or knocking down genes related to the VCAM1-CD49d signaling pathway described in 4), the gene knockout or knockdown is achieved using gene editing techniques commonly used in the art, including but not limited to lentiviral transfection systems and CRISPR-mediated gene editing systems. In a specific embodiment of the present invention, a lentiviral transfection system is used for gene knockout.

[0022] This invention's research revealed that knocking down tumor Vcam1 significantly enhances the infiltration and anti-tumor function of iNKT cells, CD8 T cells, and NK cells in tumor tissue; knocking down tumor Vcam1 further enhances the therapeutic effect of iNKT cells; in MC38 and B16F10 tumor models, CD49d antibody blockade therapy or VCAM1 antibody blockade therapy enhances the therapeutic effect of iNKT and synergistically inhibits tumor growth; indicating that VCAM1 can serve as a novel target for tumor treatment and iNKT cell immunotherapy. Furthermore, the combined use of CD49d antibody blockade therapy and iNKT cell therapy synergistically inhibits tumor growth, suggesting that CD49d can also serve as a novel target for tumor treatment and iNKT cell immunotherapy.

[0023] In this invention, the treatment of tumors includes at least one of the following:

[0024] Enhances the infiltration of at least one type of cell, including iNKT cells, CD8 T cells, and NK cells, in tumor tissue;

[0025] Reduce the size and weight of the tumor and inhibit its growth process;

[0026] Enhance the immune response of iNKT cells and promote the production of IFN-γ by iNKT cells;

[0027] It enhances the indirect activation ability of iNKT cells on CD8 T cells and NK cells, strengthens the immune response of CD8 T cells and NK cells, and promotes the production of IFN-γ.

[0028] In this invention, the tumor includes at least one of colon cancer, melanoma, low-grade glioma, and liver cancer.

[0029] In this invention, the lymphocytes include at least one of iNKT cells, CD8 T cells, NK cells, and MAIT cells.

[0030] The present invention also provides a composition comprising lymphocytes and an antibody targeting the VCAM1-CD49d signaling pathway; or comprising lymphocytes, a lymphocyte agonist and an antibody targeting the VCAM1-CD49d signaling pathway;

[0031] The antibodies against the VCAM1-CD49d signaling pathway are anti-VCAM1 antibodies and / or anti-CD49d antibodies; the lymphocytes include iNKT cells, CD8 T cells, NK cells, and MAIT cells.

[0032] The present invention also provides an antitumor drug comprising the above-described composition and a pharmaceutically acceptable carrier.

[0033] The present invention also provides a method for treating tumors, comprising: administering an inhibitor targeting the VCAM1-CD49d signaling pathway;

[0034] This may include: administration of lymphocytes, lymphocyte agonists, and inhibitors targeting the VCAM1-CD49d signaling pathway.

[0035] The administration of an inhibitor targeting the VCAM1-CD49d signaling pathway includes antibodies or small molecule drugs targeting the VCAM1-CD49d signaling pathway; specifically, the antibody may be an anti-VCAM1 antibody and / or an anti-CD49d antibody. Further, the lymphocytes include at least one of iNKT cells, CD8 T cells, NK cells, and MAIT cells. The lymphocyte agonists include αGalCer, PBS57, αGCacC8, αGCacC20:2, and OCH.

[0036] This invention reveals that knocking down the tumor Vcam1 gene can enhance iNKT cell infiltration and immune response, thereby strengthening iNKT cell-mediated anti-tumor effects. Furthermore, combining VCAM1 antibody blockade therapy or CD49d antibody blockade therapy with iNKT cell therapy synergistically inhibits tumor growth. These results confirm that the VCAM1-CD49d signaling pathway is a novel target for regulating iNKT cell infiltration and anti-tumor function, providing important evidence for new strategies to improve the efficacy of iNKT cell-related therapies, and possessing significant clinical application prospects and value. Attached Figure Description

[0037] Figure 1The knockdown of tumor Vcam1 enhances immune cell infiltration and response; (A) Statistical graph of the proportion of transfused iNKT cells, endogenous iNKT cells, CD8 T cells and NK cells in knockdown tumor tissue and control tumor tissue; (B) Statistical graph of the proportion of transfused iNKT cells, endogenous iNKT cells, CD8 T cells and NK cells with IFN-positive in knockdown tumor tissue and control tumor tissue.

[0038] Figure 2 (A) Flowchart of Vcam1 knockdown in MC38 solid tumor model combined with iNKT cell transfusion and αGC therapy; (B) Actual images of tumors in mice in different treatment groups on day 32 of tumor bearing; (C) Statistical graph of tumor weight in mice in different treatment groups on day 32 of tumor bearing; (D) Statistical graph of tumor growth in mice in different treatment groups.

[0039] Figure 3 The following diagrams illustrate how CD49d or VCAM1 antibody blockade therapy enhances the effect of iNKT therapy on MC38 tumors: (A) Flowchart of CD49d antibody blockade combined with iNKT cell therapy in MC38 tumor model; (B) Actual images of tumors in mice under different treatment groups on day 30 of tumor bearing; (C) Statistical graph of tumor weight in mice under different treatment groups on day 30 of tumor bearing; (D) Statistical graph of tumor growth in mice under different treatment groups; (E) Statistical graph of the positive proportions of iNKT cells, CD8 T cells, and NK cells with IFN-γ in mice under different treatment groups on day 30 of tumor bearing; (F) Flowchart of VCAM1 antibody blockade combined with iNKT cell therapy in MC38 tumor model; (G) Statistical graph of tumor growth in mice under different treatment groups; (H) Statistical graph of tumor weight in mice under different treatment groups on day 29.

[0040] Figure 4 This study demonstrates how CD49d or VCAM1 antibody blockade therapy enhances the effect of iNKT therapy on B16F10 tumors; (A) Flowchart of CD49d or VCAM1 antibody blockade combined with iNKT cell therapy in a B16F10 tumor model; (B) Actual images of tumors in mice under different treatment groups on day 20 of tumor bearing; (C) Statistical graph of tumor weight in mice under different treatment groups on day 20 of tumor bearing; (D) Statistical graph of tumor growth in mice under different treatment groups; (E) Statistical graph of the proportion of IFN-γ positive iNKT cells, CD8 T cells, and NK cells in mice under different treatment groups on day 20 of tumor bearing.

[0041] Figure 5 (A) Schematic diagram of the three-system in vitro experiment of human cells; (B) Statistical graph of the positive proportion of IFN-γ in human iNKT cells in different treatment groups; (C) Schematic diagram of IFN-γ production in human iNKT cells in different treatment groups. Detailed Implementation

[0042] This invention provides the application of VCAM1-CD49d signaling pathway inhibitors in the preparation of drugs for treating tumors. Those skilled in the art can refer to the content of this document and appropriately modify the process parameters to achieve the desired results. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The methods and applications of this invention have been described through preferred embodiments, and those skilled in the art can obviously make modifications or appropriate alterations and combinations to the methods and applications described herein without departing from the content, spirit, and scope of this invention to implement and apply the technology of this invention.

[0043] The test materials used in this invention are all common commercial products and can be purchased on the market.

[0044] Unless otherwise specified, all experimental materials used in the following examples were purchased from conventional biochemical reagent stores.

[0045] Wild-type (WT) mice: purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.;

[0046] Vα14 Tg cxcr6 Gfp Mice: A gift from Professor A. Bendelac's research group at the University of Chicago;

[0047] MC38: A gift from Professor Wang Yucai's research group at the University of Science and Technology of China;

[0048] B16F10: Donated by Professor Wang Yucai's research group at the University of Science and Technology of China;

[0049] HeLa.hCD1d: A gift from Professor A. Bendelac's research group at the University of Chicago;

[0050] MDA-MB-231.hVCAM1: Constructed by the inventor;

[0051] NTC MC38: Built by the inventor;

[0052] shVcam1 MC38: Constructed by the inventor;

[0053] αGC: Avanti Polar Lipid, 86700;

[0054] Zombie reactive dye: Biolegend, 423106;

[0055] Anti-mouse CD49d antibody: Bioxcell, BE0071;

[0056] Anti-mouse VCAM1 antibody: Bioxcell, BE0027;

[0057] Rat IgG isotype control antibody: Bioxcell, BE0090;

[0058] PerCP / Cy5.5 anti-mouse CD45.2 antibody: Biolegend, 109828;

[0059] APC / Cy7 anti-mouse NK1.1 antibody: Biolegend, 108724;

[0060] Pacific Blue anti-mouse TCRβ antibody: Biolegend, 108724;

[0061] BV510 anti-mouse B220 antibody: Biolegend, 103248;

[0062] BV605 anti-mouse CD8α antibody: Biolegend, 100743;

[0063] PE / Cy7 anti-mouse IFN-γ antibody: Biolegend, 505826;

[0064] Anti-human VCAM1 antibody: Biolegend, 305802;

[0065] Mouse IgG isotype control antibody: Biolegend, 400101;

[0066] FITC anti-human CD3 antibody: Biolegend, 317306;

[0067] PerCP / Cy5.5 anti-human IFN-γ antibody: Biolegend, 502526;

[0068] APC mouse CD1d-PBS57 tetramer and APC human CD1d-PBS57 tetramer: both were provided by the Emory University Tetramer Research Center of the National Institutes of Health.

[0069] The HeLa.hCD1d cell line is an artificially simulated antigen-presenting cell obtained by overexpressing human CD1d on HeLa cells. CD1d can capture the activator aGC and thus activate NKT.

[0070] In this invention, MDA-MB-231.hVCAM1 is a cell line that overexpresses the human VCAM1 gene (full length) on human MDA-MB-231 cells, wherein the overexpression vector used is (pcDNA3.1). shVcam1 MC38 refers to a cell line obtained by knocking down the Vcam1 gene using shRNA technology on the mouse colon cancer cell line MC38. NTC MC38 serves as the knockdown control: a cell line transfected with scramble shRNA without the target gene. All three cell lines can be constructed using conventional methods in the art.

[0071] The present invention will be further illustrated below with reference to the embodiments:

[0072] Example 1: Tumor VCAM1's ability to inhibit effector cell infiltration and immune response

[0073] 1. Amplification of mouse iNKT-GFP cells

[0074] (1)Vα14 Tgcxcr6 Gfp Mouse spleen tissue was ground into a single-cell suspension using a 200-mesh copper mesh. The suspension was centrifuged at 1500 rpm for 5 minutes. The precipitate was then lysed with erythrocyte lysis buffer for 2 minutes, and lysis was terminated by adding 10% fetal bovine serum-1640 medium.

[0075] (2) Centrifuge at 1500 r / min for 5 min. Add 10% fetal bovine serum-1640 medium to the precipitate and mix well. Adjust the cell density to 2 × 10⁶ cells / min. 6 / ml, and add 100 IU / ml IL-2 and 100 ng / ml αGC to the cell suspension.

[0076] (3) Place in a 37℃, 5% CO2 cell culture incubator for 4 days.

[0077] (4) Collect all cell suspensions and centrifuge at 1500 rpm for 5 min. Resuspend the pellet in 10% fetal bovine serum-1640 medium containing 100 IU / ml IL-2 and adjust the cell density to 1×10⁻⁶ cells / ml. 6 / ml.

[0078] (5) When the cell density exceeds 2×10 6 When the volume is 1 ml, the cells are separated using a half-change method.

[0079] (6) On days 10-14 of culture, dead cells were removed using Ficoll solution. The cell suspension and Ficoll solution were added at a 1:1 ratio (top and bottom volumes), and centrifuged at 500g for 15 minutes at room temperature with an ascent rate of 1 and a descent rate of 0. The middle white membrane layer after centrifugation is the amplified iNKT-GFP cell.

[0080] 2. shRNA lentiviral transfection to knock down the Vcam1 gene in MC38 cells

[0081] (1) Select HEK-293T cells cultured in 10cm culture dishes with a cell density of 80% to 90%.

[0082] (2) Mix 500 μl of Opti-MEM, 12 μg of VCAM1 shRNA plasmid or Scramble shRNA control plasmid, 3.5 μg of pMD2G and psPAX2 thoroughly to prepare reaction solution 1. Preheat at 37℃ for 5 min; mix 500 μl of Opti-MEM with 66 μg of PEI thoroughly to prepare reaction solution 2. (The sequence of VCAM1 shRNA is: CCAGATCCTTAATACTGTTTA)

[0083] (3) Slowly add reaction solution 1 to reaction solution 2, mix well, and let stand at room temperature for 30 minutes. Slowly and evenly add the mixture to a 10cm culture dish.

[0084] (4) Change the medium after 6-8 hours and add 10 ml of 5% FBS-DMEM medium. After culturing for 72 hours, collect the cell supernatant and filter the supernatant through a 0.22 μm filter. The obtained supernatant is the virus stock solution.

[0085] (5) Select MC38 cells cultured in 10cm culture dishes with a cell density of 80%–90%, remove the cell supernatant, add 4ml of virus stock solution, and add Polybrene to a final concentration of 8μg / ml. After 6–8 hours of infection, add 8ml of 10% FBS-DMEM complete medium evenly.

[0086] (6) 48 h after infection, cells were passaged and knockdown efficiency was tested. Puromycin was added to a final concentration of 1 μg / ml during cell passage to maintain the phenotypic profile. The Vcam1 knockdown group consisted of shVcam1 MC38 cells, and the negative control group consisted of NTC MC38 cells.

[0087] 3. Knocking down the tumor Vcam1 gene enhances the infiltration of iNKT cells, CD8 T cells, and NK cells within the tumor and improves the immune response.

[0088] (1) Knockdown of the Vcam1 gene increases tumor cell apoptosis. Therefore, in this experiment, different numbers of tumor cells were implanted while the tumor was bearing the tumor to ensure that the tumor tissue size was consistent during experimental treatment. WT mice were implanted with 1×10⁶ tumor cells. 6 NTC MC38 cells and 1.5 × 10 6 One shVcam1 MC38 cell.

[0089] (2) On the 8th day after tumor implantation, 2×10⁻⁶ cells were transferred intravenously. 7 One amplified iNKT-GFP cell.

[0090] (3) On the 10th day of tumor bearing, αGC (2μg / animal) was injected intraperitoneally.

[0091] (4) Four hours after intraperitoneal injection, the mice were sacrificed and their spleen and tumor tissues were removed.

[0092] (5) Spleen tissue was ground into a single-cell suspension using a 200-mesh copper mesh. Centrifuged at 1500 r / min for 5 min. The precipitate was lysed with erythrocyte lysis buffer for 2 min, and 1% bovine serum albumin-PBS solution was added to stop the lysis. After centrifugation for 5 min, the precipitate was the extracted spleen lymphocytes.

[0093] (6) The tumor tissue was minced and added to 0.1% collagenase IV-PBS solution. The mixture was placed on a shaker at 37°C and digested at 200 rpm for 45 min. Digestion was terminated by adding 1% bovine serum albumin-PBS solution. The tissue suspension was vortexed and passed through a 200-mesh copper mesh. The cell suspension was collected and centrifuged at 2000 rpm for 10 min. An appropriate amount of 40% Percoll solution was added according to the amount of precipitate and mixed well. Half the volume of 70% Percoll solution was slowly added along the tube wall to the lower layer of the 40% Percoll solution. The mixture was centrifuged at room temperature, with an ascent rate of 6 and a descent rate of 2, at 2000 rpm for 20 min. The middle white membrane layer represents the tumor lymphocytes.

[0094] (7) Collect the lymphocytes extracted from (5) and (6) and perform surface staining to label iNKT cells, CD8T cells and NK cells, and perform intracellular staining to detect the expression of IFN-γ in various cells.

[0095] Based on the indirect activation effect of iNKT cells on CD8 T cells and NK cells, in vivo injection of mouse lipid antigen αGC activated intratumoral iNKT cells promoted the activation of CD8 T cells and NK cells. Knockdown of tumor Vcam1 led to increased infiltration of transfused iNKT cells (GFP-positive), endogenous iNKT cells (GFP-negative), CD8 T cells, and NK cells within the tumor, and an increased cell ratio. Figure 1A). Simultaneously, knockdown of tumor Vcam1 promotes iNKT cell activation and the production of the cytokine IFN-γ, enhances the indirect activation capacity of iNKT cells against CD8 T cells and NK cells, and increases the immune response of CD8 T cells and NK cells, as well as IFN-γ production. Figure 1 B).

[0096] Example 2: Knocking down tumor Vcam1 combined with iNKT cell therapy enhances the anti-tumor effect of iNKT cells and inhibits tumor growth.

[0097] (1) WT mice were loaded with 1×10 6 NTC MC38 cells and 1.5 × 10 6 One shVcam1 MC38 cell.

[0098] (2) On day 8 of tumor-bearing, tumor-bearing mice were randomly divided into groups:

[0099] Group 1: Tumor-bearing NTC MC38 cells, treated with PBS solution as a control;

[0100] Group 2: Tumor-bearing NTC MC38 cells, treated with iNKT cell transfusion and αGC therapy;

[0101] Group 3: Tumor-bearing shVcam1 MC38 cells, treated with PBS solution as a control;

[0102] Group 4: tumor-bearing shVcam1 MC38 cells, treated with iNKT cell transfusion and αGC therapy.

[0103] (3) On day 8 of tumor bearing, mice in the iNKT cell therapy group received 2×10⁻⁶ cells via intravenous transfer to the tail vein. 7 A number of iNKT-GFP cells were amplified, and the same volume of PBS solution was transferred into the tail vein of control mice.

[0104] (4) On the 10th day of tumor bearing, mice in the iNKT cell therapy group were injected intraperitoneally with αGC (2μg / mouse), while mice in the control group were injected intraperitoneally with the same volume of PBS solution.

[0105] (5) Starting from the 8th day of tumor bearing, measure the length and width of the tumor every other day. Volume = length × width × height (1 / 2 width).

[0106] (6) On day 32 of tumor bearing, when the tumor volume of mice exceeded 2000 mmHg. 3 Treatment was terminated in cases where the condition was not met, and the tumor weight of mice in different treatment groups was recorded.

[0107] The mice were treated according to their groups, and the tumor growth was observed. Figure 2 A) iNKT cell therapy effectively inhibits tumor growth and reduces tumor weight. Figure 2 (BD). Knocking down tumor Vcam1 synergistically enhances the efficacy of iNKT cell therapy and further inhibits tumor growth. Figure 2 BD).

[0108] Example 3: In the MC38 tumor model, CD49d antibody blockade therapy or VCAM1 antibody blockade therapy effectively enhanced the therapeutic effect of iNKT cell therapy and synergistically inhibited tumor growth.

[0109] 1. CD49d antibody blockade therapy enhances the efficacy of iNKT cell therapy and synergistically inhibits the growth process of MC38 solid tumors.

[0110] (1) WT mice were loaded with 1×10 6 One MC38 cell.

[0111] (2) On day 7 of tumor-bearing, tumor-bearing mice were randomly divided into groups:

[0112] Group 1: iNKT cell transfusion and αGC treatment, followed by treatment with rat IgG isotype control antibody;

[0113] Group 2: iNKT cell transfusion and αGC treatment, with treatment with anti-mouse CD49d antibody.

[0114] (3) On day 8 of tumor bearing, 2×10⁻⁶ mice were transfused via the tail vein of each group of mice. 7 One amplified iNKT-GFP cell.

[0115] (4) Starting from the 9th day of tumor bearing, mice were injected intraperitoneally every two days according to their groups with anti-mouse CD49d antibody (10 mg / kg) or rat IgG isotype control antibody (10 mg / kg) on ​​the 9th, 12th, 15th, 18th, 21st, 24th and 27th days, respectively.

[0116] (5) On the 10th day of tumor bearing, each group of mice was injected intraperitoneally with αGC (2μg / mouse).

[0117] (6) Starting from the 7th day of tumor bearing, measure the length and width of the tumor every other day. Volume = length × width × height (1 / 2 width).

[0118] (7) On day 30 of tumor bearing, when the tumor volume of mice exceeded 2000 mmHg. 3 Treatment was terminated in cases where the condition was not met, and the tumor weight of mice in different treatment groups was counted and lymphocytes were extracted from the tumor tissue.

[0119] (8) Collect and extract tumor tissue lymphocytes for surface staining to label iNKT cells, CD8 T cells and NK cells, and perform intracellular staining to detect the expression of IFN-γ in each cell.

[0120] Mice were treated in groups, and tumor growth in different treatment groups was observed. Figure 3 A) Blocking CD49d signaling effectively enhances the therapeutic effect of iNKT cells, reduces tumor weight, and further inhibits tumor growth. Figure 3 BD). Flow cytometry analysis revealed that CD49d antibody blockade significantly enhanced the anti-tumor effect of iNKT cells, strengthened the indirect activation ability of iNKT cells on CD8 T cells and NK cells, and further improved the anti-tumor capabilities of CD8 T cells and NK cells. Figure 3 E).

[0121] 2. VCAM1 antibody blockade therapy enhances the efficacy of iNKT cell therapy and synergistically inhibits the growth process of MC38 solid tumors.

[0122] (1) WT mice were loaded with 1×10 6 One MC38 cell.

[0123] (2) On day 7 of tumor-bearing, tumor-bearing mice were randomly divided into groups:

[0124] Group 1: iNKT cell transfusion and αGC treatment, followed by treatment with rat IgG isotype control antibody;

[0125] Group 2: iNKT cell transfusion and αGC treatment, followed by treatment with anti-mouse VCAM1 antibody.

[0126] (3) On day 8 of tumor bearing, 2×10⁻⁶ mice were transfused via the tail vein of each group of mice. 7 One amplified iNKT-GFP cell.

[0127] (4) Starting from the 9th day of tumor bearing, mice were injected intraperitoneally every two days according to their groups with anti-mouse VCAM1 antibody (10 mg / kg) or rat IgG isotype control antibody (10 mg / kg) on ​​the 9th, 12th, 15th, 18th, 21st, 24th and 27th days, respectively.

[0128] (5) On the 10th day of tumor bearing, each group of mice was injected intraperitoneally with αGC (2μg / mouse).

[0129] (6) Starting from the 8th day of tumor bearing, measure the length and width of the tumor every other day. Volume = length × width × height (1 / 2 width).

[0130] (7) On day 29 of tumor bearing, when the tumor volume of mice exceeded 2000 mmHg. 3 Treatment was terminated in the following cases, and the tumor weight of mice in different treatment groups was recorded.

[0131] Mice were treated in groups, and tumor growth in different treatment groups was observed. Figure 3F), blocking VCAM1 signaling effectively enhances the therapeutic effect of iNKT cell therapy, reduces tumor weight, and further inhibits tumor growth. Figure 3 GH).

[0132] Example 4: In the B16F10 tumor model, blocking VCAM1-CD49d signaling effectively enhanced the therapeutic effect of iNKT cells and synergistically inhibited tumor growth.

[0133] (1) WT mice were loaded with 2×10 5 One B16F10 cell.

[0134] (2) On day 8 of tumor-bearing, tumor-bearing mice were randomly divided into groups:

[0135] Group 1: iNKT cell transfusion and αGC treatment, followed by treatment with rat IgG isotype control antibody;

[0136] Group 2: iNKT cell transfusion and αGC treatment, followed by treatment with anti-mouse CD49d antibody;

[0137] Group 3: iNKT cell transfusion and αGC treatment, with treatment with anti-mouse VCAM1 antibody.

[0138] (3) On day 8 of tumor bearing, 2×10⁻⁶ mice were transfused via the tail vein of each group of mice. 7 One amplified iNKT-GFP cell.

[0139] (4) Starting from the 9th day of tumor bearing, mice were injected intraperitoneally every two days according to their groups with anti-mouse CD49d antibody (10 mg / kg), anti-mouse VCAM1 antibody (10 mg / kg), or rat IgG isotype control antibody (10 mg / kg), and the drugs were administered on the 9th, 12th, 15th and 18th days, respectively.

[0140] (5) On the 10th day of tumor bearing, each group of mice was injected intraperitoneally with αGC (2μg / mouse).

[0141] (6) Starting from the 7th day of tumor bearing, measure the length and width of the tumor every other day. Volume = length × width × height (1 / 2 width).

[0142] (7) On day 20 of tumor bearing, when the tumor volume of mice exceeded 2000 mmHg. 3 Treatment was terminated in cases where the condition was not met, and the tumor weight of mice in different treatment groups was counted and lymphocytes were extracted from the tumor tissue.

[0143] (8) Collect and extract tumor tissue lymphocytes for surface staining to label iNKT cells, CD8 T cells and NK cells, and perform intracellular staining to detect the expression of IFN-γ in each cell.

[0144] Mice were treated in groups, and tumor growth in different treatment groups was observed. Figure 4 A) Blocking VCAM1-CD49d signaling with CD49d antibody or VCAM1 antibody enhances the therapeutic effect of iNKT cell therapy, reduces tumor weight, and further inhibits tumor growth. Figure 4 BD). Flow cytometry analysis revealed that both VCAM1 antibody blockade and CD49d antibody blockade significantly enhanced the anti-tumor effect of iNKT cells, increased the indirect activation ability of iNKT cells on CD8 T cells and NK cells, and further improved the anti-tumor ability of CD8 T cells and NK cells. Figure 4 E).

[0145] Example 5: Human tumor VCAM1 inhibits the activation of human iNKT cells

[0146] 1. Expanding human iNKT cells

[0147] (1) The proportion of iNKT cells in human tissues and blood is low. Therefore, this experiment used human peripheral blood PBMCs to obtain a large number of human iNKT cells through in vitro expansion. Human peripheral blood PBMCs were separated using Ficoll solution at room temperature, centrifuged at a rising rate of 1 and a falling rate of 0, at 500g for 15min. The intermediate white membrane layer after centrifugation is the PBMC.

[0148] (2) Add 10% fetal bovine serum-1640 human lymphocyte complete culture medium to PBMC and wash twice. Centrifuge at 1500 r / min for 5 min.

[0149] (3) Add 10% fetal bovine serum-1640 human lymphocyte complete culture medium to the precipitate and mix well. Adjust the cell density to 4 × 10⁻⁶ cells / mL. 6 / ml, and add 200 IU / ml IL-2 and 1 μg / ml αGC to the cell suspension.

[0150] (4) Place in a 37℃, 5% CO2 cell culture incubator for 4 days.

[0151] (5) Collect all cell suspensions and centrifuge at 1500 rpm for 5 min. Resuspend the pellet in 10% fetal bovine serum-1640 human lymphocyte complete culture medium containing 200 IU / ml IL-2 and adjust the cell density to 1×10⁻⁶. 6 / ml.

[0152] (6) When the cell density exceeds 2×10 6 When the volume is 1 ml, the cells are separated using a half-change method.

[0153] (7) On days 10-14 of culture, use Ficoll solution to remove dead cells.

[0154] 2. Blocking VCAM1 signaling in human tumors effectively promotes the activation of human iNKT cells and the production of the cytokine IFN-γ.

[0155] (1) Digest MDA-MB-231.hVCAM1 cells and HeLa.hCD1d cells in the logarithmic growth phase.

[0156] (2) Add 1×10 according to the group. 5 1 MDA-MB-231.hVCAM1 cell and 1×10 5 HeLa.hCD1d cells were evenly seeded into plates, and αGC or an equal volume of PBS solution was added to each group to a final concentration of 1 μg / ml.

[0157] Group 1: PBS, used to expand human iNKT cells, HeLa.hCD1d cells, and PBS negative control.

[0158] Group 2: αGC, expanded human iNKT cells, HeLa.hCD1d cells, PBS negative control

[0159] Group 3: αGC, expanded human iNKT cells, HeLa.hCD1d cells, MDA-MB-231.hVCAM1 cells, mouse IgG isotype control antibody

[0160] Group 4: αGC, expanded human iNKT cells, HeLa.hCD1d cells, MDA-MB-231.hVCAM1 cells, anti-human VCAM1 antibody

[0161] (3) After culturing for 10–12 hours, remove the supernatant and add 2×10⁻⁶ mol / L. 5 Expand human iNKT cells and add anti-human VCAM1 antibody, mouse IgG isotype control antibody or an equal volume of PBS solution to a final concentration of 5 μg / ml according to the group.

[0162] (4) After 12 hours of co-culture, cells were collected and the production of IFN-γ in human iNKT cells was detected.

[0163] The co-culture system involves adding different types of cells and treatment drugs in sequence and groups. Figure 5 A). Flow cytometry was used to detect the production of the cytokine IFN-γ in human iNKT cells from different treatment groups. Statistical analysis revealed that co-culturing tumor cell lines overexpressing human VCAM1 with human iNKT cells effectively inhibited the activation of human iNKT cells. Figure 5 Using VCAM1 antibody to block VCAM1-CD49d signaling significantly restored the immune response of human iNKT cells and promoted the production of cytokine IFN-γ by human iNKT cells. Figure 5 BC).

[0164] References

[0165] 1.Brennan,P.J.,M.Brigl and M.B.Brenner(2013)."Invariant natural killer T cells:an innate activation scheme linked to diverse effector functions."Nat Rev Immunol 13(2):101-117.

[0166] 2.Fu,S.,K.He,C.Tian,H.Sun,C.Zhu,S.Bai,J.Liu,Q.Wu,D.Xie,T.Yue,Z.Shen,Q.Dai,X.Yu,S.Zhu,G.Liu,R.Zhou,S.Duan,Z.Tian,T.Xu,H.Wang and L.Bai(2020)."Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells."Nat Commun 11(1):438.

[0167] 3.Fu,S.,S.Zhu,C.Tian,S.Bai,J.Zhang,C.Zhan,D.Xie,L.Wang,Z.Li,J.Li,H.Zhang,R.Zhou,Z.Tian,T.Xu and L.Bai(2019)."Immunometabolism regulates TCR recycling and iNKT cell functions."Sci Signal 12(570).

[0168] 4.Fujii,S.I.and K.Shimizu(2019)."Immune Networks and Therapeutic Targeting of iNKT Cells in Cancer."Trends Immunol 40(11):984-997.

[0169] 5. Nelson, A., JDLukacs and B.Johnston(2021). "The Current Landscape ofNKT Cell Immunotherapy and the Hills Ahead." Cancers (Basel) 13(20).

[0170] 6.Tang, R., 12:648917.

[0171] 7.Xie, D., S. Zhu and L. Bai (2016). "Lactic acid in tumormicroenvironments causes dysfunction of NKT cells by interfering with mTORsignaling." Sci China Life Sci 59(12):1290-1296.

[0172] The above are merely preferred embodiments of the present invention. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. Application of inhibitors targeting the VCAM1-CD49d signaling pathway in combination with lymphocyte immunotherapy agents in the preparation of drugs for treating tumors; The lymphocyte immunomodulator is composed of lymphocytes and lymphocyte agonists; The lymphocytes are iNKT cells; The lymphocyte agonist is αGalCer; The tumor is colon cancer; The inhibitors targeting the VCAM1-CD49d signaling pathway are anti-VCAM1 antibodies and / or anti-CD49d antibodies; The treatment of tumors includes reducing the size and weight of the tumor and inhibiting the tumor's growth process.

2. Use according to claim 1, characterized in that, The tumor treatment includes at least one of the following: Enhances the infiltration of at least one type of cell, including iNKT cells, CD8 T cells, and NK cells, in tumor tissue; Enhance the immune response of iNKT cells and promote the production of IFN-γ by iNKT cells; It enhances the indirect activation ability of iNKT cells on CD8 T cells and NK cells, strengthens the immune response of CD8 T cells and NK cells, and promotes the production of IFN-γ.

3. Composition, characterized in that, Including inhibitors targeting the VCAM1-CD49d signaling pathway and lymphocyte immunotherapy agents; The lymphocyte immunomodulator is composed of lymphocytes and lymphocyte agonists; The lymphocytes are iNKT cells; The lymphocyte agonist is αGalCer; The antibodies used in the VCAM1-CD49d signaling pathway are anti-VCAM1 antibodies and / or anti-CD49d antibodies.

4. An antitumor drug, characterized in that, Includes the composition of claim 3 and a pharmaceutically acceptable carrier.